Clinical implications for loss or diminution of expression of Raf-1 kinase inhibitory protein and its phosphorylated form in ductal breast cancer.

摘要: Raf Kinase inhibitory protein (RKIP) is a well-established metastasis suppressor that frequently downregulated in aggressive cancers. The impact of RKIP and its phosphorylated form on disease-free survival (DFS) other clinicopathological parameters breast cancer yet to be discovered. To this end, we examined expression 3 independent cohorts. At the Protein level, loss or reduced total was associated with large-sized tumors characterized by high proliferative index, high-grade diminished estrogen (ER) progesterone receptor expression. Loss diminution significantly shorter DFS all Moreover, complete p-RKIP an prognostic factor using multivariate analysis operable invasive ductal cancer. We show for first time ER, partly, drives through MTA3-Snail axis. Consistent finding, found that, at mRNA varied across different molecular subtypes Luminal (ER+) subtype expressing levels more Claudin-low (ER-) subtype, which depicted highest epithelial mesenchymal transition (EMT) registered lowest levels. In conclusion, expression/diminution poor diseases-free Determining adds significant value management subtyping disease.